DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Venoferrum- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Venoferrum ...
January 2019
35 pages
Ventorlin Expectorant- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ventorlin Expectorant ...
January 2019
35 pages
Veramyst- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Veramyst ...
January 2019
35 pages
Vfend- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Vfend ...
January 2019
35 pages
Victrelis- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Victrelis ...
January 2019
35 pages
Vidaza- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Vidaza ...
January 2019
35 pages
Vimpat- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Vimpat ...
January 2019
35 pages
Viread- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Viread ...
January 2019
35 pages
Vivanza- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Vivanza ...
January 2019
35 pages
Volibris- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Volibris ...
January 2019
35 pages
Votrient- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Votrient ...
January 2019
35 pages
Votubia- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Votubia ...
January 2019
35 pages
Vyvanse- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Vyvanse ...
January 2019
35 pages
Xanax- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xanax ...
January 2019
35 pages
Xarelto- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xarelto ...
January 2019
35 pages
Xelevia- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xelevia ...
January 2019
35 pages
Xeloda- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xeloda ...
January 2019
35 pages
Xenazine- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xenazine ...
January 2019
35 pages
Xeristar- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xeristar ...
January 2019
35 pages
Xeroquel LP- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xeroquel ...
January 2019
35 pages
Xopenex- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xopenex ...
January 2019
35 pages
Xtandi- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xtandi ...
January 2019
35 pages
Xyrem- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xyrem ...
January 2019
35 pages
Xyzall- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Xyzall ...
January 2019
35 pages
Zactos- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zactos ...
January 2019
35 pages
Zaldiar- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zaldiar ...
January 2019
35 pages
Zeclar- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zeclar ...
January 2019
35 pages
Zeffix- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zeffix ...
January 2019
35 pages
Zelboraf- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zelboraf ...
January 2019
35 pages
Zelitrex- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zelitrex ...
January 2019
35 pages
Zemplar- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zemplar ...
January 2019
35 pages
Zenhale- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zenhale ...
January 2019
35 pages
Zienam- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zienam ...
January 2019
35 pages
Zient- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zient ...
January 2019
35 pages
Zintrepid- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zintrepid ...
January 2019
35 pages
Zispin- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zispin ...
January 2019
35 pages
Zocor- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zocor ...
January 2019
35 pages
Zoloft- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zoloft ...
January 2019
35 pages
Zoltec- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zoltec ...
January 2019
35 pages
Zortress- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zortress ...
January 2019
35 pages
Zosyn- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zosyn ...
January 2019
35 pages
Zurcal- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zurcal ...
January 2019
35 pages
Zyprexa- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zyprexa ...
January 2019
35 pages
Zytiga- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zytiga ...
January 2019
35 pages
Zyvoxid- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Zyvoxid ...
January 2019
35 pages
Acromegaly - Market Insight, Epidemiology and Market Forecast - 2028
US$ 6,250.00
... in Acromegaly Acromegaly Pipeline Analysis Acromegaly Market Size and Trends Acromegaly Market Opportunities Impact of upcoming Therapies in Acromegaly Acromegaly Report Key Strengths 10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Acromegaly ...
January 2019
100 pages
Adempas- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Adempas ...
January 2019
35 pages
Adlyxin- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Adlyxin ...
January 2019
35 pages
Akynzeo- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Akynzeo ...
January 2019
35 pages
Alecensa- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Alecensa ...
January 2019
35 pages
